This article is more than 5 years old. Information may no longer be current.
Enrollment begins in trial of polymer-free coronary stent
Click Here to Manage Email Alerts
Biotronik announced the first enrollments in a trial assessing the safety and efficacy of a new coronary stent to treat de novo coronary artery lesions.
The polymer-free coronary stent (Biovitesse, Biotronik) combines a new anti-proliferative limus drug, designed to prevent excess cell growth, with ultrathin struts, according to a press release issued by the company.
The trial is a multicenter, first-in-man study of the stent for the treatment of coronary de novo lesions and will assess strut coverage as verified by OCT at 1 month and in-stent late lumen loss as verified by quantitative coronary angiography at 9 months, according to the release.
“As an established and trusted provider of a leading vascular intervention portfolio, Biotronik has once again demonstrated its commitment to innovation by the development of this new coronary stent system,” Daniel W. Buehler, MD, president of vascular intervention at Biotronik, said in the release. “Our Biovitesse stent system’s ease of use reflects our long-term expertise in developing coronary stents, which allows us to continue to improve performance and provide enhanced treatment options.”
Disclosure: Buehler is an employee of Biotronik.